medigraphic.com
ISSN 1561-302X (Print)

2021, Number 2

Next >>

Rev cubana med 2021; 60 (2)

The arrival of biological inhibitors for preventing migraine

Ruiz LA, Signes RS, Cano VA

Language: Spanish
References: 14
Page: 1-3
PDF size: 210.79 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Camporeale A, Kudrow D, Sides R, Wang S, Van Dycke A, Selzler KJ, et al. A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine. BMC Neurol. 2018;18(1):188. https://doi.org/10.1186/s12883-018-1193-2

  2. Charles A, Pozo-Rosich P. Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet. 2019;394(10210): 1765-74. https://doi.org/10.1016/S0140-6736(19)32504-8

  3. The Lancet Neurology. Complicated decisions on new migraine-prevention therapies. Lancet Neurol. 2019;18(3):221. https://doi.org/10.1016/S1474-4422(19)30041-9

  4. Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):2211-21. https://doi.org/10.1212/WNL.0000000000006640

  5. Ren Z, Zhang H, Wang R, Yuan Q, Pan L, Chen C. The treatment efficacy of galcanezumab for migraine: A meta-analysis of randomized controlled trials. Clin Neurol Neurosurg. 2019;186:105428. https://doi.org/10.1016/j.clineuro.2019.105428

  6. Goadsby PJ, Dodick DW, Martinez JM, Ferguson MB, Oakes TM, Zhang Q, et al. Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis. J Neurol Neurosurg Psychiatry. 2019;90(8):939-44. https://doi.org/10.1136/jnnp-2018-320242

  7. Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, et al. A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med. 2017;377:2123-32.

  8. Hershey A. CGRP - The next frontier for migraine. N Engl J Med. 2017;377:2190-91. https://www.nejm.org/doi/full/10.1056/nejmoa1705848

  9. Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, et al. Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine. N Engl J Med. 2019;381:142-49. https://www.nejm.org/doi/full/10.1056/nejmoa1811090

  10. Silberstein SD, Stauffer VL, Day KA, Lipsius S, Wilson MC. Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2). J Headache Pain. 2019 Jun 28;20(1):75. https://doi.org/10.1186/s10194-019-1024-x

  11. Tessitore A, Russo A. Is targeting CGRP the right pathway to prevent migraine? Lancet. 2019;394(10203):984-86. https://twitter.com/thelancet/status/1163726006299045888?lang=es

  12. Tringali G, Navarra P. Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis. Peptides. 2019;116:16-21. https://doi.org/10.1016/j.peptides.2019.04.012

  13. Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392(10161):2280-7. https://doi.org/10.1016/S0140-6736(18)32534-0

  14. Yuan H, Spare NM, Silberstein SD. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review. Headache. 2019;59 (2):20-32. https://doi.org/10.1111/head.13583




2020     |     www.medigraphic.com